Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multiple-doses, Randomised, Double-blind, Three-periods, Two-sequences Crossover Study to Assess the Immunogenicity and Pharmacodynamic Comparability of a Biosimilar Pegfilgrastim (B12019) and the Reference Product Neulasta® in Healthy Subjects

NCT02912377 is registered in ClinicalTrials.gov with Cinfa Biotech as lead sponsor.

NCT NCT02912377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02912377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multiple-doses, Randomised, Double-blind, Three-periods, Two-sequences Crossover Study to Assess the Immunogenicity and Pharmacodynamic Comparability of a Biosimilar Pegfilgrastim (B12019) and the Reference Product Neulasta® in Healthy Subjects
Lead sponsor
Cinfa Biotech
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2016
Completion date
May 31, 2017
Enrollment
96 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers